313 related articles for article (PubMed ID: 35493498)
1. Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.
Escalante GM; Mutsvunguma LZ; Muniraju M; Rodriguez E; Ogembo JG
Front Immunol; 2022; 13():867918. PubMed ID: 35493498
[TBL] [Abstract][Full Text] [Related]
2. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
3. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
Herrman M; Mühe J; Quink C; Wang F
J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.
Edwards KR; Schmidt K; Homad LJ; Kher GM; Xu G; Rodrigues KA; Ben-Akiva E; Abbott J; Prlic M; Newell EW; De Rosa SC; Irvine DJ; Pancera M; McGuire AT
Cell Rep Med; 2024 Jun; 5(6):101587. PubMed ID: 38781964
[TBL] [Abstract][Full Text] [Related]
6. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
[TBL] [Abstract][Full Text] [Related]
7. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.
Escalante GM; Foley J; Mutsvunguma LZ; Rodriguez E; Mulama DH; Muniraju M; Ye P; Barasa AK; Ogembo JG
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32268575
[TBL] [Abstract][Full Text] [Related]
8. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
9. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
10. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
11. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
[TBL] [Abstract][Full Text] [Related]
12. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.
Malhi H; Homad LJ; Wan YH; Poudel B; Fiala B; Borst AJ; Wang JY; Walkey C; Price J; Wall A; Singh S; Moodie Z; Carter L; Handa S; Correnti CE; Stoddard BL; Veesler D; Pancera M; Olson J; King NP; McGuire AT
Cell Rep Med; 2022 Jun; 3(6):100658. PubMed ID: 35705092
[TBL] [Abstract][Full Text] [Related]
13. Urgency and necessity of Epstein-Barr virus prophylactic vaccines.
Zhong L; Krummenacher C; Zhang W; Hong J; Feng Q; Chen Y; Zhao Q; Zeng MS; Zeng YX; Xu M; Zhang X
NPJ Vaccines; 2022 Dec; 7(1):159. PubMed ID: 36494369
[TBL] [Abstract][Full Text] [Related]
14. The need and challenges for development of an Epstein-Barr virus vaccine.
Cohen JI; Mocarski ES; Raab-Traub N; Corey L; Nabel GJ
Vaccine; 2013 Apr; 31 Suppl 2(0 2):B194-6. PubMed ID: 23598481
[TBL] [Abstract][Full Text] [Related]
15. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
Sashihara J; Hoshino Y; Bowman JJ; Krogmann T; Burbelo PD; Coffield VM; Kamrud K; Cohen JI
PLoS Pathog; 2011 Oct; 7(10):e1002308. PubMed ID: 22028652
[TBL] [Abstract][Full Text] [Related]
16. Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination.
Stewart JP; Micali N; Usherwood EJ; Bonina L; Nash AA
Vaccine; 1999 Jan; 17(2):152-7. PubMed ID: 9987149
[TBL] [Abstract][Full Text] [Related]
17. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
18. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
19. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
20. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
